What Health Advances does

Health Advances is a privately held, healthcare- and life-sciences-focused boutique strategy consulting firm founded around 1996 (firmographics note 1992) and headquartered at 275 Grove Street in Newton, Massachusetts. The firm was co-founded by Paula Ness Speers and Mark Speers, who continue as Senior Advisors, and is led operationally by a Managing Partner and Global Head (Sheela Hegde) alongside Practice Heads for Biopharma (Vivek Mittal, PhD), MedTech, Digital Health and HIT (Susan A. Posner), Commercial and Growth (Greg Chittem), and Diagnostics, Precision Medicine and Life Science Tools (Donna Hochberg, PhD). Health Advances operates through wholly-owned subsidiaries in San Francisco, Zug, Switzerland (Health Advances GmBH), and Hong Kong (Health Advances Asia Limited), and reports engagement activity across 80 countries.

The firm offers six core consulting capabilities — Corporate Strategy, Product Development & Portfolio Strategy, Go-to-Market & Commercial Strategy, Business Development Strategy, Commercial Diligence, and Market Access & Pricing — delivered across five sectors (Biotech & Pharmaceuticals, Diagnostics/Precision Medicine/Life Science Tools, MedTech, Digital Health & Enterprise HIT, and Investors) and 14+ therapeutic-area practices including Cell & Gene Therapy, Oncology, CNS, Cardiovascular, Diabetes & Metabolics, and Rare Diseases. Service delivery relies on human capital (staff with MD, PhD, and PharmD credentials), proprietary sector-specific databases and expert networks, and a formal strategic alliance with CRO Parexel that provides client access to ex-FDA/EMEA clinical and regulatory advisors.

Health Advances generates revenue through professional-services engagements on a project-by-project basis; pricing is not publicly disclosed and is negotiated by scope, team composition, and requirements. Customers span 1,000+ companies and investors (from early-stage biotech to large pharma, plus private equity and venture capital), served via a sales-led motion through direct consulting engagements. Cumulative scale includes 3,500+ assignments completed and consistent Vault #1 rankings for Formal Training. The firm has no disclosed outside equity, no acquisitions, and no public revenue figures; operations are organic, partner-led, and global.

Name

Health Advances

Legal name

Health Advances LLC

Website

https://healthadvances.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

51–100 employees

Short description

Health Advances is a privately held, healthcare- and life-sciences-only boutique strategy consulting firm serving biotech, pharma, MedTech, diagnostics, digital health companies, and healthcare investors across 80 countries from offices in Newton, San Francisco, Zug, and Hong Kong.

Ownership category

akta.pro rank

Product category

Healthcare and Life Sciences Consulting

NAICS

Human Resources Consulting Services (541612), Management Consulting Services (54161)

SIC

Services-Management Consulting Services (8742), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Healthcare IT & Health Informatics Staffing (BPACADAK)

akta.pro secondary industry

Healthcare & Life Sciences Leadership Search (BPACAAAE)

Keywords

• Healthcare consulting
• Life sciences advisory
• Strategic consulting
• Commercial diligence
• Biopharma advisory

Headquarters

HQ city

Weston

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Strategic Consulting Services: Health Advances generates revenue through providing strategic consulting services to healthcare and life sciences companies. They offer corporate strategy, product development, go-to-market, business development, and commercial diligence services. The firm works with early-stage startups to large pharmaceutical companies, serving as trusted advisors on strategic questions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Health Advances is a boutique healthcare and life sciences consulting firm that delivers strategic advisory services to biopharmaceutical, diagnostics, MedTech, and digital health companies, as well as healthcare investors. Its core offerings span five consulting capabilities: corporate strategy, product development and portfolio strategy, go-to-market and commercial strategy, business development strategy, and commercial diligence. The firm has supported over 1,000 companies and investors across 3,500+ assignments, organized across sector and therapeutic practice areas with deep domain expertise and proprietary databases.

Product overview

Health Advances is a healthcare and life sciences consulting firm offering strategic advisory services across five core consulting engagements: Corporate Strategy, Product Development & Portfolio Strategy, Go-to-Market & Commercial Strategy, Business Development Strategy, and Commercial Diligence. The firm works with over 1,000 companies and investors on over 3,500 assignments. These services are organized by sector expertise (Biotech & Pharmaceuticals, Diagnostics Precision Medicine & Life Science Tools, MedTech, Digital Health & Enterprise HIT, and Investors) and therapeutic practices (Allergy & Immunology, Bioprocessing, Cardiovascular, Cell & Gene Therapy, CNS Diseases, Contract Pharma Services, Diabetes & Metabolics, Digital Therapeutics, Drug Delivery Devices, Life Science Tools & Services, Oncology, Precision Medicine, Rare Diseases, Real-World Data & Analytics, Women's Health). The consulting engagements are delivered through practice-specific teams with deep expertise, proprietary databases, and networks of external experts.

Differentiator

Problem solved

Functional benefit

Products and services

• Corporate Strategy Strategic advisory service focused on making hard choices that give healthcare and life sciences companies the focus necessary to achieve sustainable competitive advantage.
• Product Development & Portfolio Strategy Consulting service focused on thoughtful prioritization and sharp strategy to translate innovation into commercial value, including clinical development paths, target product profiles, and portfolio optimization.
• Go-to-Market & Commercial Strategy Strategic advisory on stakeholder buying processes, reimbursement, business models, ideal customer profiles, and global commercialization strategies for new health technologies.
• Business Development Strategy Advisory service to prioritize growth opportunities that leverage right-to-win, strategic fit, and optimize portfolio value.
• Commercial Diligence Data-driven, rigorously quantified assessments to gain realistic pictures of opportunities, spot synergies, and prepare for deal-making, including buy-side and sell-side due diligence for investors and corporate acquirers.
• Market Access & Pricing Advisory on integrating value and access considerations early and throughout trials and product lifecycle to maximize commercial potential, including evidence generation, cost containment measures, HTA pathways, and reimbursement strategies.

Quantifiable outcome

• Worked with over 1,000 companies and investors on over 3,500 assignments
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• ParexelcoreStrategic or Co-development PartnerHealth Advances has a formal relationship with Parexel, a leading CRO. Parexel colleagues include medical directors who have designed and executed clinical trials across virtually every therapeutic area, and regulatory experts who provide practical advice from their years at FDA, EMEA and other global authorities. This collaboration enhances Health Advances' ability to offer comprehensive strategic advisory services spanning clinical development and regulatory strategy.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Trinity Life Sciences: Life sciences commercial strategy and insights firm serving biopharma clients across portfolio strategy, launch, and market access. Direct peer: comparable boutique-to-mid-size scale, overlapping therapeutic-area depth, and expanding investment in proprietary data and analytics assets.
• ZS Associates: Global consulting firm focused on healthcare and related industries, with deep biopharma commercial and sales/marketing expertise. Direct peer: serves the same pharma/biotech buyer base with overlapping go-to-market, commercial strategy, and launch advisory offerings.
• Simon-Kucher & Partners: Global consultancy with a major Healthcare & Life Sciences practice, particularly strong in pricing, market access, and commercial strategy. Direct peer where engagements overlap on market access, pricing, and go-to-market work for biopharma clients.
• Charles River Associates: Global consulting firm with a Life Sciences practice offering strategic and economic advisory services to pharma, biotech, and MedTech clients. Direct peer on commercial strategy, pricing/market access, and life sciences due diligence mandates.
• ClearView Healthcare Partners: Boutique strategy consulting firm focused exclusively on the life sciences industry, covering corporate strategy, therapeutic area strategy, and commercial diligence. Direct peer by both business model (boutique, healthcare-only) and service offerings; primary competition in commercial diligence work for PE/VC clients.
• Putnam Associates: Boutique life sciences strategy consulting firm specializing in biopharma commercial strategy, portfolio prioritization, and launch planning. Direct peer by both scale and service mix — comparable boutique model serving similar biotech/pharma strategy and commercial diligence needs.
• LEK Consulting: Global strategy consultancy with one of the largest dedicated healthcare and life sciences practices. Closest direct competitor: similar boutique-to-mid-size positioning, comparable client mix across pharma/biotech/MedTech, and overlapping service lines in corporate strategy, commercial diligence, and product portfolio strategy.

Broad incumbents

• Bain & Company (Healthcare Practice): Global strategy consultancy with a strong healthcare and life sciences practice serving biopharma, MedTech, and PE healthcare investors. Broad incumbent: directly competes on commercial diligence and corporate strategy engagements, particularly for PE/VC healthcare clients.
• McKinsey & Company (Pharma & Medical Products Practice): Global management consultancy with one of the largest healthcare practices covering biopharma, MedTech, and healthcare systems. Broad incumbent: competes on the same corporate strategy, portfolio, and commercial diligence mandates but with vastly larger bench and broader industry portfolio.
• Boston Consulting Group (Healthcare Practice): Global strategy consultancy with a major healthcare practice serving pharma, biotech, MedTech, and providers. Broad incumbent: overlapping corporate strategy and portfolio advisory work, with much greater scale and integrated delivery capability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/healthadvances
• Facebookfacebook.com/health-advances-llc-56688262271
• LinkedInlinkedin.com/company/health-advances

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Health Advances